Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs. Here, we will give a short insight into our published results.


Update: March 4th, 2019; enrolled patients: 18,154

Amgevita┬« (Adalimumab)     7
Benepali┬« (Etanercept)  538
Cimzia┬« (Certolizumab)   868
Enbrel® (Etanercept)2855
Erelzi┬« (Etanercept)  139
Flixabi┬« (Infliximab)      1
Humira® (Adalimumab)2897
Hyrimoz┬« (Adalimumab)    10
Imraldi┬« (Adalimumab)     6
Inflectra┬« (Infliximab)    16
Kevzara┬« (Sarilumab)    52
Kineret┬« (Anakinra)    89
MabThera┬« (Rituximab) 1464
Olumiant┬« (Baricitinib)   231
Orencia┬« (Abatacept)   743
Remicade┬« (Infliximab)   762
Remsima┬« (Infliximab)      9
Rixathon┬« (Rituximab)      2
RoActemra┬« (Tocilizumab) 1297
Simponi┬« (Golimumab)   435
Xeljanz┬« (Tofacitinib)   176
Control Group 5557